Pseudomonas aeruginosa – an environmental bacteria that can cause devastating multidrug-resistant infections, particularly in people with underlying lung conditions – evolved rapidly and then spread globally over the last 200 years, probably driven by changes in human behaviour, a new study has found.
A major new institute opens today, bringing together the largest concentration of scientists and clinicians in heart and lung medicine in Europe.
Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients – showing that it can evolve rapidly within an individual during chronic infection.
World-leading AI technology developed by the Cambridge Centre for AI in Medicine and their colleagues – some of which is being showcased this week at the North American Cystic Fibrosis Conference 2020 – offers a glimpse of the future of precision medicine, and unprecedented predictive power to clinicians caring for individuals with the life-limiting condition.
A new app, which will be used to collect data to develop machine learning algorithms that could automatically detect whether a person is suffering from COVID-19 based on the sound of their voice, their breathing and coughing, has been launched by researchers at the University of Cambridge.
Almost 30 years on from the discovery of the genetic defect that causes cystic fibrosis, treatment options are still limited and growing antibiotic resistance presents a grave threat. Now, a team of researchers from across Cambridge, in a major new centre supported by the Cystic Fibrosis Trust, hopes to turn fortunes around.
A multi-drug resistant infection that can cause life-threatening illness in people with cystic fibrosis (CF) and can spread from patient to patient has spread globally and is becoming increasingly virulent, according to new research published today in the journal Science.
GSK, the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust today announce their Strategic Partnership, with the long-term ambition to jointly deliver new medicine to patients in the next 5-10 years.
Almost one in four of the world’s cases of tuberculosis (TB) are in India and the disease is constantly adapting itself to outwit our medicines. Could the answer lie in targeting not the bacteria but its host, the patient?
The University of Cambridge has been awarded £2 million from the UK Medical Research Council and the Government of India’s Department for Biotechnology to develop a partnership with the National Institute for Research in Tuberculosis (NIRT) in Chennai.
© 2025 University of Cambridge